Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
FFuji Pharma Co.,Ltd. logo
4554TSE Prime

Fuji Pharma Co.,Ltd.

富士製薬工業 Yahoo Finance

Recent & upcoming events

Aug 6
Earnings 2:00
Q3 earnings announcement (scheduled)
Add to Google Calendar
May 12
Earnings 2:00
Q2 earnings announcement (scheduled)
Add to Google Calendar
Feb 5
Earnings 1:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
2025
Dec 18
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
Nov 11
Earnings 1:00
FY earnings announcement (scheduled)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Nov 10
Est.
Earnings 1:00 approx.
Full-year earnings
Add to Google Calendar
2027
Jan 28
Est.
Earnings 1:00 approx.
Q1 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Apr 22
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
Jul 15
Est.
Earnings 2:00 approx.
Q3 earnings
Add to Google Calendar

KPI highlights

FY25
Revenue ¥51.68B YoY +12.0%
Operating income ¥4.99B margin 9.7%
Net income ¥3.00B YoY -51.2%
EPS ¥123 YoY -51.4%
P/E —
ROE 6.5% Equity ratio 50% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2026/09 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥59.25B +14.7%
Operating income ¥6.12B +22.6%
Net income ¥2.24B -25.3%
EPS ¥92 -25.5%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q4FY25 Q4
Revenue ¥10.26B¥11.41B¥10.75B¥10.64B——
Operating income ¥579M¥1.46B¥-140M¥1.58B——
Net income ¥210M¥1.45B¥2.74B¥1.52B——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2021–2025）

創業家 17.6%事業法人 4.1%国内機関 13.1%海外機関 5%個人 20.9%未開示 37.8%20212022202320242025
創業家事業法人国内機関海外機関個人その他未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

有限会社FJP 17.6%有限会社FJP今井　博文 12.5%今井　博文日本マスタートラスト信託銀行株式会社 8.8%日本マスタートラスト信託銀行株式会社(信託口)新井　規子 5.1%新井　規子Lotus Japan Holdin 5%Lotus Japan Holdings合同会社株式会社日本カストディ銀行(信託口) 4.3%株式会社日本カストディ銀行(信託口)株式会社Yamhill Scienc 4.1%株式会社Yamhill Sciences今井　道子 1.8%今井　道子公益財団法人今井精一記念財団 1.6%公益財団法人今井精一記念財団20212022202320242025

Top shareholders — actual figures (as of 2025)

Holder Shares held Ratio Source
有限会社FJP 4,307,000 17.6% Yuho (EDINET)
今井 博文 3,052,000 12.5% Yuho (EDINET)
日本マスタートラスト信託銀行株式会社(信託口) 2,159,000 8.8% Yuho (EDINET)
新井 規子 1,240,000 5.1% Yuho (EDINET)
Lotus Japan Holdings合同会社 1,219,000 5.0% Yuho (EDINET)
株式会社日本カストディ銀行(信託口) 1,046,000 4.3% Yuho (EDINET)
株式会社Yamhill Sciences 1,000,000 4.1% Yuho (EDINET)
今井 道子 446,000 1.8% Yuho (EDINET)
公益財団法人今井精一記念財団 400,000 1.6% Yuho (EDINET)
富士製薬工業従業員持株会 372,000 1.5% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

6/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 3.2%
✓ Positive operating cash flow ¥5.80B
✗ ROA improved YoY 6.8% → 3.2%
✓ Operating CF exceeds net income (accrual quality) OCF ¥5.80B / net income ¥3.00B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 50.6% → 50.2%
✓ Current ratio improved 1.19× → 1.55×
✗ No dilution (shares outstanding did not increase) 24,753,800 → 24,891,100
✓ Gross margin improved 38.7% → 40.2%
✓ Asset turnover improved 0.51× → 0.55×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio 50.2%
Current ratio 1.5×
Years of positive operating CF 9 of last 10 yrs
Payout ratio 45%
Latest fiscal year result Profit (net income ¥3.00B)

Performance history

Last 10 years
0億円129億円258億円388億円517億円 FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

Income & assets

Unit: ¥100M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue 342354379363338340354409461517
Operating income 35.743.143.941.731.433.537.838.638.849.9
Ordinary income 32.546.344.741.729.832.537.345.244.544.6
Net income 21.233.033.729.620.924.327.034.461.530.0
Total assets 481496531607620642755853900934
Equity 292326354394400327358412456469

Indicators & cash flow

*Split-adjustedUnit: ¥100M
Item FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
EPS ¥71¥110¥113¥97¥67¥91¥111¥141¥253¥123
ROE 7.3%10.7%9.9%7.9%5.3%6.7%7.9%8.9%14.2%6.5%
Operating CF 45.132.437.770.457.759.9-6.5819.241.558.0
Investing CF -33.2-15.3-10.7-120-26.2-23.5-113-52.4-16.6-42.2
Financing CF 0.78-30.4-20.072.74.50-54.450.919.2-4.359.54
FCF 11.917.027.0-49.931.536.5-119-33.224.915.8

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Key financial metrics

3-year revenue growth ✓ Dividend grower ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data